The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of patient-reported outcomes (PROs) to predict treatment outcomes in patients with advanced cancer.
 
Aparna Raj Parikh
Consulting or Advisory Role - Foundation Medicine; Lilly; Natera; PureTech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); Tesaro (Inst)
 
Emily E. Van Seventer
No Relationships to Disclose
 
Madeleine Fish
No Relationships to Disclose
 
Kathryn Fosbenner
No Relationships to Disclose
 
Katie Kanter
No Relationships to Disclose
 
Amirkasra Mojtahed
No Relationships to Disclose
 
Jill N. Allen
No Relationships to Disclose
 
Lawrence Scott Blaszkowsky
Stock and Other Ownership Interests - Pfizer (I)
 
Jeffrey William Clark
Research Funding - Pfizer (Inst)
 
Jon S. Du Bois
No Relationships to Disclose
 
Joseph Wang Franses
Stock and Other Ownership Interests - Biogen; Merck
Consulting or Advisory Role - Foundation Medicine
 
Bruce J. Giantonio
No Relationships to Disclose
 
Lipika Goyal
Consulting or Advisory Role - Agios; Alentis Therapeutics; AstraZeneca; Debiopharm Group; H3 Biomedicine; Incyte; Klus Pharma; QED Therapeutics; Sirtex Medical; Taiho Pharmaceutical
(OPTIONAL) Uncompensated Relationships - Agios; Debiopharm Group; Taiho Pharmaceutical
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Foundation Medicine; Lilly; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - Astellas Pharma (Inst); Leap Therapeutics (Inst)
 
Eric Roeland
Consulting or Advisory Role - AIM Specialty Health; Asahi Kasei; BASF; HERON; Immuneering; Mitobridge; Napo Pharmaceuticals; Oragenics; Oragenics; Pfizer/EMD Serono; Vector Oncology
Expert Testimony - Regents of the University of California
 
David P. Ryan
Stock and Other Ownership Interests - Acworth Pharmaceuticals; MPM Capital
Honoraria - Research to Practice; UpToDate
Consulting or Advisory Role - Gritstone Bio; Maverick Therapeutics; MPM Capital; Oncorus; TCR2 Therapeutics; Twentyeight-Seven Therapeutics
Research Funding - Stand up to Cancer (Inst)
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties
Other Relationship - TCR2 Therapeutics
 
Colin D. Weekes
Honoraria - Bayer; Celgene; Lilly; Merrimack
Consulting or Advisory Role - Celgene; Ipsen; Merrimack
Research Funding - Abbvie; AstraZeneca; Bayer; Celgene; Genentech/Roche; Gilead Sciences; Halozyme; Ipsen; Lilly; Millennium
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly
 
Nora K. Horick
No Relationships to Disclose
 
Ryan Bruce Corcoran
Stock and Other Ownership Interests - Avidity Biosciences; C4 Therapeutics; Fount Therapeutics; Kinnate Biopharma; nRichDx; Revolution Medicines
Consulting or Advisory Role - Abbvie; Amgen; Array BioPharma; Astex Pharmaceuticals; Avidity Nanomedicines; Bristol-Myers Squibb; C4 Therapeutics; Chugai Pharma; Elicio Therapeutics; FOGPharma; Fount Therapeutics; Genentech; Ipsen; Kinnate Biopharma; Loxo; Merrimack; N-of-One; Natera; Novartis; nRichDx; Revolution Medicines; Roche; Roivant; Shionogi; Shire; Spectrum Pharmaceuticals; Symphogen; Taiho Pharmaceutical; Warp Drive Bio; Zikani Therapeutics
Research Funding - Asana Biosciences; AstraZeneca; Lilly; Sanofi
 
Ryan David Nipp
No Relationships to Disclose